Advances in Diagnosis and Therapeutic Strategies for Uveal Melanoma
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 197
Special Issue Editor
Special Issue Information
Dear Colleagues,
Uveal melanoma is a highly aggressive malignancy, often resistant to radiation and systemic therapies, including immune checkpoint inhibitors. Recent advances have brought significant progress in treating metastatic uveal melanoma, with FDA-approved therapies such as tebentafusp, the PKC inhibitor darovasertib, and the liver-directed HEPZATO KIT (melphalan for injection/hepatic delivery system). These therapies have shown improved overall response rates (ORRs) and patient survival compared to standard treatments. However, challenges remain. For instance, tebentafusp improves overall survival but achieves measurable tumor shrinkage in only 5–11% of patients. This underscores the need to enhance therapeutic efficacy and expand benefits to more patients. Meanwhile, emerging insights into the genetic, transcriptomic, and immune landscapes of uveal melanoma open new avenues for developing novel and more effective treatment strategies. Furthermore, the clinical implementation of therapies such as tebentafusp, darovasertib, and HEPZATO KIT has underscored the importance of optimizing treatment management and addressing emerging challenges, including therapy-associated side effects. For this Special Issue, we invite authors to contribute papers exploring innovations in translational drug discovery, and advancements in the diagnosis and clinical management of uveal melanoma. Our aim is to provide a platform for advancing knowledge and improving outcomes for patients with this challenging disease.
Dr. Yong Qin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- immunotherapy
- targeted therapy
- biomarker
- disease management
- drug development
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
